(NASDAQ: PULM) Pulmatrix's forecast annual revenue growth rate of 26.83% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.96%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.23%.
Pulmatrix's revenue in 2024 is $7,298,000.On average, 1 Wall Street analysts forecast PULM's revenue for 2024 to be $25,346,858, with the lowest PULM revenue forecast at $25,346,858, and the highest PULM revenue forecast at $25,346,858. On average, 1 Wall Street analysts forecast PULM's revenue for 2025 to be $25,602,518, with the lowest PULM revenue forecast at $25,602,518, and the highest PULM revenue forecast at $25,602,518.
In 2026, PULM is forecast to generate $60,080,088 in revenue, with the lowest revenue forecast at $60,080,088 and the highest revenue forecast at $60,080,088.